Preclinical studies have demonstrated that downregulating CD47 can enhance phagocytosis, promote tumor regression, and improve survival outcomes across multiple cancer types, including colorectal, lung, breast, leukemia, and lymphoma.,, Here, CD47 is linked to neoplasm.